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Treatment guidelines for patients with schizophrenia recommend evaluating their risk of 
physical comorbidities, especially since these patients are known to have decreased life 
expectancy due to comorbidities. Therefore, to the authors’ knowledge, this is the first 
national survey conducted to investigate how Italian psychiatrists deal with the risk of 
physical comorbidities and sexual dysfunction in patients with schizophrenia. A sample of 
750 psychiatrists completed an ad hoc online survey investigating their decision making 
about performing blood tests, clinical and instrumental examinations, and scheduling 
follow-up appointments in relation to the different phases of the illness and possible 
pharmacological side effects. Compared to patients in therapeutic continuation, those 
diagnosed for the first time and those who received a therapeutic change were visited more 
frequently (every 15 to 17 days vs. every 40 days, respectively), and were more regularly 
prescribed blood tests and instrumental examinations (every 4.2 to 4.4 months vs. every 9 
months, respectively). There was a high interest in the surveillance of cardiometabolic risk. 
In 54% of patients, prolactin testing was not requested before starting an antipsychotic. In 
terms of specialist referrals, only 5% of surveyed psychiatrists “never” sought for additional 
counseling. There was little attention given to sexual functioning assessment based on the 
survey results about patients' daily life and with regard to deciding to prescribe additional 
examinations. In fact, only up to 3% of psychiatrists reported assessing sexual functioning 
using specific psychometric tests. In summary, Italian psychiatrists describes themselves 
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InTrODUCTIOn
In persons with schizophrenia, the high prevalence of medical 
comorbidities and resulting mortality is an alarming and 
worldwide phenomenon with negative short- and long-term 
health effects (1). Compared to the general population, life 
expectancy may be shortened by 10 to 20 years due to the 
increased risk of physical comorbidities was reported (2). The 
high prevalence of comorbidities has been conceptualized as 
the result of several factors such as side effects of pharmacological 
treatments and the adoption of unhealthy lifestyle behaviors 
characterized by physical inactivity, poor quality of food intake, 
smoking habits, and reduced social functioning (3). However, 
it is also widely known that physical well-being of people with 
schizophrenia has been historically ignored, including data 
for monitoring basic parameters like blood pressure and body 
weight (4).
The inadequate monitoring and treatment of metabolic 
abnormalities was previously documented by the CATIE study 
(5). A large Danish population-based study from 2000 to 2012 
revealed that for people with a first-time schizophrenia diagnosis, 
the highest reported rate of metabolic monitoring was 71%, with 
more than a half of patients having an abnormal lipid profile 
and more than 10% with blood glucose imbalance (6). There 
is growing evidence that persons with schizophrenia continue 
to be victims of healthcare disparities due to their decreased 
healthcare access and use, and healthcare professionals’ 
insufficient consideration of the poor physical health outcomes 
of the physical illnesses and lifestyle choices in this group of 
people (7). Moreover, addressing sexual dysfunction in persons 
with psychotic disorders remains an unmet need but a key health 
determinant (8). For instance, surveillance and pharmacological 
care of sexual dysfunction were reported to be lacking in patients 
with mental disorders (9).
These shortcomings in healthcare access and provision may 
contribute to life-threatening events that need to be addressed. 
Thus, improvement of physical comorbidities in people with 
schizophrenia is now considered to be a necessary management 
goal and has been included in treatment guidelines (10). 
Therefore, for the first time, we conducted a national survey 
investigating how Italian psychiatrists who treat persons with 
schizophrenia deal with their patients’ physical comorbidities 
and sexual dysfunctions. The primary goal of the survey was 
to investigate psychiatrists’ decision making about performing 
blood tests and clinical and instrumental examinations, and 
scheduling follow-up appointments with respect to the different 
phases of their patients’ illness and possible pharmacological 
side effects.
MATErIAlS AnD METhODS
Study Participants
Participants were 750 Italian psychiatrists working in different 
clinical settings, mainly public mental health services (see below 
Table 1). Participation was voluntary. Study participants were 
enrolled by distributing a brochure containing a brief summary 
of the research proposal and the link to the online survey. The 
flyer was allocated in conferences, outpatient and inpatients 
clinics. Once logged, the psychiatrists were authorized to 
as careful healthcare providers for the physical illnesses of patients with schizophrenia 
but with several shortcomings. For instance, clinical attention toward patients’ sexual and 
reproductive healthcare needs remains a challenge. Psychiatrists should take the lead for 
the integrated education, assessment, and care of medical needs of their patients with 
mental illness. Based on the results of this survey, the authors also believe that a future 
challenge for the management of patients with mental illness will be the classification of 
patients based on their risk of comorbidities, to help ensure optimal healthcare provision 
for those at greater risk of other illnesses.
Keywords: schizophrenia, physical comorbidities, sexual dysfunction, cardiometabolic risk, antipsychotic, 
prolactin, psychometric test, survey
TABlE 1 | Demographics of study participants.
Percentage
Sex
Male 54% (N = 407)
Female 46% (N = 343)
Age (years)
<40 25% (N = 188)
41–50 23% (N = 174)
51–60 31% (N = 236)
>60 20% (N = 152)
Years of activity
<10 26% (N = 192)
11–20 25% (N = 191)
21–30 31% (N = 231)
>30 18% (N = 136)
Region of provenance
Northern Italy 44% (N = 328)
Central Italy 23% (N = 174)
Southern Italy and 
Islands
33% (N = 248)
Practice setting
Outpatient clinic 61% (N = 455)
Inpatient setting 28% (N = 208)
Residential setting 6% (N = 44)
Private practice 6% (N = 43)
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withdraw a portion of or their entire response to the survey if 
they decided to pull out from the study; consequently, any data 
or recordings obtained from these participants were destroyed 
and were not allowed to be used in any resulting publication. 
Psychiatrists were also informed that the answers to the survey 
were confidential and anonymous. They were guaranteed that 
none of the information provided would be used for direct 
marketing or other non-research activities. Given the design of 
recruitment, psychiatrists were free to decline their participation 
to the study without addressing it. Accordingly, the response rate 
to the survey was not available. Ethics approval was not required 
as per local legislation and national guidelines.
Survey
Data were collected via computer-assisted telephone interviewing 
(C.A.T.I.) and computer-assisted web interviewing (C.A.W.I.) 
of a random group of 750 psychiatrists, from February 2018 to 
February 2019. The authors representing a scientific committee 
of national experts with a special interest in the comorbidities of 
people with schizophrenia drafted an ad hoc 15-min questionnaire 
based on published guidelines for writing surveys (11, 12). The 
complete English translation of the survey may be referred to in 
the Supplementary Materials, and includes questions about:
i) The characteristics of the psychiatrists (gender, age, years of 
working experience, working in inpatients vs. an outpatient 
setting, Italian region of provenance)
ii) The characteristics of the psychiatrists’ activity (number 
of patients seen per months, percentage of patients with 
schizophrenia)
iii) The characteristics of patients affected by schizophrenia 
(phase of illness, number of patients with known vs. first-time 
diagnosis of schizophrenia)
iv) Percentage of patients for whom psychiatrists decided for 
therapy continuation against patients in which they preferred 
changing therapy, in terms of adding or removing a drug or 
changing its dosage. Factors influencing the decision to change 
the treatment (efficacy, side effects, physical comorbidity, 
others)
v) Information about pharmacological side effects that are 
declared by patients (type of side effects, side effects reported 
as more disturbing)
vi) Frequency of clinical assessments, prescriptions of blood 
tests, instrumental examination, and clinical referral
vii) How often the psychiatrists ask the patient about physical 
comorbidity indicators and pharmacological side effects 
(sleep disorders, tremors, body weight changes, sexual 
dysfunctions, waist circumference, gynecomastia, family 
history of cardiovascular disease, musculoskeletal disorders, 
urinary dysfunctions, respiratory tract diseases)
viii) How often the psychiatrists ask the patient about unhealthy 
lifestyle behaviors (dietary patterns, physical activity, 
substance abuse, behavioral addiction such as sex, computers, 
and gaming, smoking habits, alcohol abuse, misuse of 
psychotropic-prescribed medications, private relationships, 
sexual activities, sexual orientation, functioning in relation to 
self-care)
Analysis
Data collected from the web-based survey tool were analyzed 
using the SAS (Statistical Analysis System) for data control. The 
statistical tables were constructed by NIPO Diana System (NIPO 
Software, a Kantar Company).
The chi-squared (χ2) test with 95% confidence interval was 
used for statistical significance calculation between percentages. 
The Student's t-test with 95% confidence interval was used for 
statistical significance calculation between means.
rESUlTS
Characteristics of the Participant 
Psychiatrists
Sample characteristics are presented in Table 1. Of the 750 
psychiatrists included in this non-interventional study, 54% were 
men and 46% were women. The mean age was 50 ( ± 11.26) years 
(range: 25–76), the mean years of working experience was 20 ( ± 
11.36) years (range: 1–50). The provenance of participants was 
equally spread across Italy. The majority of participants worked 
in an outpatient's public setting.
The Characteristics of the Psychiatrists’ 
Activity (Total Sample)
Each psychiatrist visited a mean number of 96 ( ± 71.2) patients 
per month (range: 10–600), of whom 28% had schizophrenia, 
28% had bipolar disorder, and 44% had other mental disorders.
The Characteristics of Patients Affected 
by Schizophrenia
Three out of 10 patients visited by clinicians suffered from 
schizophrenia (min–max: 1–280). With regard to the course 
of illness, approximately two out of three patients (min–max: 
1–100) were in a stable phase and one out of three were in 
an acute exacerbation phase of illness (68% as against 32%). 
Psychiatrists reported that of a mean of 100 patients visited 
monthly, approximately 14% (min–max: 1–100) received a 
diagnosis of schizophrenia for the first time, 30% (min–max: 
1–100) underwent treatment changes, and 55% (min–max: 
1–100) received treatment confirmation.
The Factors Influencing Psychiatrists 
Deciding to Change the Therapy
Of all the respondents, about 34% of psychiatrists reported 
that they changed patient’s therapy due to side effects, 19% due 
to physical comorbidities, and 47% due to treatment failure or 
inadequate efficacy.
Information About Pharmacological Side 
Effects reported by Patients
According to the psychiatrists, weight gain, extrapyramidal 
side effects, and sexual dysfunction were the most reported and 
most bothersome symptoms for patients with schizophrenia. 
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Metabolic problems were also frequent (79%) but fewer patients 
reported it as bothersome (22%). Fewer patients also reported 
cardiovascular problems and arterial hypertension as bothersome 
(i.e., 5 and 3%, respectively) (Figure 1).
Frequency of Clinical Assessments, 
Prescriptions of Blood Tests, Instrumental 
Examinations, and Clinical referral
As shown in Figure 2A, patients who received a diagnosis for the 
first time and patients who have changed therapy were visited 
more frequently compared to patients in therapeutic continuation 
(every 15 to 17 days vs. every 40 days, respectively). A χ2 test was 
performed to assess the differences between the three groups, as 
shown in Figure 2B.
In the three groups of patients the examinations more 
frequently required were electrocardiogram and measurements 
of blood cholesterol, triglycerides, glucose, and liver enzymes. 
Prolactin level evaluation was requested more often when the 
psychiatrist decided to change the therapy (Table 2, question—
D9: In detail, what tests do you require for the three different 
types of patients?).
The analysis of comorbidity management in collaboration 
with other specialists showed that 47% of responders “frequently” 
asked for a specialist referral. Cardiologists, internal medicine 
specialists, and endocrinologists were the most frequently 
involved specialists. (Figure 3, question—D12: In approaching 
and managing medical comorbidities, do you usually consult a 
specialist?).
Frequency of Assessment of Troublesome 
Issues in the Patients With Schizophrenia
Sleep disturbances and tremors were the most investigated 
aspects. Body weight and sexual dysfunctions were also assumed 
as very important by the specialists. The family history of 
FIgUrE 1 | Most frequent and bothersome problems for people with schizophrenia, as reported by psychiatrists.
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FIgUrE 2 | (A) Check-up frequency in patients with schizophrenia. (B) Check-up frequency in patients with schizophrenia: the differences between groups 
(χ2 test).
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cardiovascular disease was mainly investigated at the first visit 
(Figure 4, question—D10: Regardless of the type of patient, how 
often do you investigate the following aspects?).
Frequency of the Analysis of Aspects 
related to the Patient's Everyday life
Use of psychotropic prescribed drugs, substances, and alcohol, 
including abuse, misuse, and/or dependence, were the most 
commonly investigated aspects of patient's daily life. Sexual 
function was the most highly neglected aspect by clinicians 
(Figure 5, question—D11: And how often do you investigate the 
following aspects of everyday life?).
DISCUSSIOn
In persons with schizophrenia, premature mortality is primarily due 
to preventable physical diseases. Hence, the aim of this survey was 
to understand the current attitudes of Italian psychiatrists regarding 
this threatened population. The sample of our study included 
clinicians working in different clinical settings, including outpatient 
and inpatient care, from across Italy, to provide a closer picture of 
their real-life practice. We aimed to explore if the psychiatrists 
were adequate in inquiring about comorbidities and lifestyle 
habits, in prescribing blood tests, instrumental examinations, and 
psychometric questionnaires. We also investigated if there was an 
intent of minimizing the risk of comorbidities from the beginning of 
the therapeutic process. Furthermore, we examined the frequency 
pattern of patient assessments and laboratory examinations 
throughout the various phases of the patients' illness, specifically 
in first-time diagnosis patients, patients in therapeutic change, and 
patients in treatment continuation.
We found a monthly fairly high-incidence of first time diagnosis 
of schizophrenia (14%) and a high rate of pharmacological switchers 
(30%). This result may be due to the psychiatrists’ clinical setting of 
provenience. In fact, the majority of participants worked in acute 
inpatients setting and outpatients units that were characterized by a 
high rate of check-up.
Patients diagnosed for the first time with schizophrenia and 
those who were received a therapeutic change were visited more 
frequently vs. patients in therapeutic continuation (every 15–17 
days vs. every 40 days, respectively). Similarly, blood tests and 
instrumental examinations were more regularly prescribed for 
those diagnosed for the first time and those who were received 
a therapeutic change vs. those in therapeutic continuation (every 
4.2–4.4 months vs. every 9 months, respectively). Regarding the 
kind of examinations required, we observed that, in general, 
psychiatrists tend to prescribe more examinations for the newly 
diagnosed patients vs. the other patient groups. Meanwhile, 
blood prolactin value was more frequently requested for patients 
in treatment change vs. those in the newly diagnosed group. 
Hence, it appears that more than half of patients (54%) are not 
stratified according to basal prolactin levels before starting an 
antipsychotic treatment. This is an important finding because 
treatment with first- and second-generation antipsychotics 
is often associated with hyperprolactinemia, warranting the 
need to obtain baseline prolactin measurements and constant 
monitoring to guide follow-up therapy decisions and shifting 
strategies (13).
On the other hand, Italian psychiatrists showed high interest 
in screening for cardiovascular disease risk, including obtaining 
an electrocardiogram and measuring patients’ total lipid profile 
and blood pressure. In particular, the close monitoring of the 
corrected QT interval was in line with the recommendation 
of the Italian Medicines Agency (AIFA) that is the national 
authority responsible for drugs regulation in Italy. It is worth 
noting that in people with schizophrenia, the prevalence of 
cardiovascular disease was found to be 2.5 times higher than the 
general population (14). Moreover, while the last four decades 
has shown a global reduction in cardiovascular mortality 
(15), this has not been the case for patients with severe mental 
disorders (16).
The surveyed psychiatrists also often examined patients’ 
metabolic profile in terms of glycemia, triglyceridemia, 
cholesterolemia, and body weight. Weight gain, in particular, 
was conceived as the most common and bothersome problem for 
patients. Previous data of patients survey on subjective quality of 
life showed that the diagnosis of schizophrenia was correlated with 
low physical functioning (17). Moreover, patients with metabolic 
syndrome and schizophrenia perceived a higher number of care 
needs, lower global functioning score, and poor adherence to 
treatment (18–20). There is general acquiescence that treatment 
with second-generation antipsychotics may cause weight gain in 
patients with schizophrenia (21); however, weight gain in general 
TABlE 2 | Required examinations for the different types of patients 
with schizophrenia.
Question: In detail, what tests do you require for the three different types 
of patients?
Patients being 
diagnosed for 
the first time1
Patients in 
therapeutic 
change2
Patients in 
therapeutic 
continuation3
Electrocardiogram 96* 89* 86*
Cholesterol blood level 89* 81* 86*
Fasting blood sugar level 88* 82* 79*
Triglycerides blood levels 88* 80* 81*
Liver enzymes levels 86* 80* 79*
Blood pressure 80* 72* 68*
Blood tests of renal 
function
77* 71* 69*
Serum electrolyte levels 75* 67* 64*
Thyroid hormone levels 69* 53* 45*
Prolactin levels 56* 69* 59*
Illicit drug metabolites 43 22 14
HIV-hepatitis testing 27 13 9
Prostate-specific antigen 
test
9 6 8
Sex hormones 6 5 5
Mammography 3 2 4
PAP test 3 2 3
Psychometric tests for 
sexual functioning
3 2 2
Fecal occult blood test 2 2 1
1Percentage based on a total number of 718 psychiatrists. 2Percentage based 
on a total number of 712 psychiatrists. 3Percentage based on a total number of 
711 psychiatrists. *95% statistically significant difference.
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is multifactorial and is affected by socioeconomic disadvantages, 
unhealthy lifestyle, and premorbid genetic vulnerabilities.
Schizophrenia per se may be an independent risk factor for 
metabolic disorders and obesity (22). In fact, a “developmental” 
type of obesity has been proposed in the 1950s as a defense 
against mental illness (23). Accordingly, turning to overeating 
and obesity may be conceived as protections from premorbid 
threatening sensations and feeling that are characteristic of the 
schizophrenic development. To date, PubMed has indexed over 
2,000 manuscripts on the topic of weight gain and schizophrenia. 
For example, available literature proposes that insulin resistance 
occurs before obesity development and the use of antipsychotic 
medications, although these likely play a complicating key role 
later in the progression of schizophrenia (24).
In summary, our results confirm that surveyed Italian 
psychiatrists recognize the importance of effective monitoring of 
patients’ cardiometabolic risk. Data was particularly encouraging 
compared to previous epidemiological studies, which reported a 
mean of 8 to 30% testing rates in person with serious mental illness 
who started treatment with a new antipsychotic (25, 26). However, 
while the surveyed Italian psychiatrists reported that weight gain 
was a frequent presentation in patients with schizophrenia (79%), 
on the other hand they believed that patients underestimated 
the detrimental impact of metabolic problems, with only 22% 
of cases reporting weight gain as bothersome. The apparent 
unawareness of patients regarding the important consequences of 
metabolic abnormalities may serve as a catalyst for mental health 
professionals to educate patients, their family, and caregivers, and 
provide ad hoc psycho-education interventions (27).
The analysis of the collaboration with other specialists showed 
that almost half of responders “frequently” (47%) and “sometimes” 
(48%) asked for a specialist referral, with only 5% “never” seeking 
additional consult. The most commonly consulted specialists 
were cardiologists, internists, and endocrinologists. Only 
1% of the surveyed psychiatrists reported consultations with 
nutritionists or dieticians. Because available data documented 
that individuals with severe mental disorders are often victims 
of suboptimal healthcare systems (28, 29), our results about the 
psychiatrists’ “frequently” turning to medical specialists was 
reasonable. The factors contributing the inequitable access to 
FIgUrE 3 | Question—D12: In approaching and managing medical comorbidities, do you usually consult a specialist?
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physical care and treatment are multiple, including difficulties 
with interactions between healthcare providers, separation of 
responsibilities and disorganized care, and patient's barriers to 
recognizing the need for specialist intervention. Many people 
with severe mental illness also experience discrimination due 
to their diagnosis, including from general practitioners or in 
the general healthcare context (30). Moreover, psychiatrists may 
feel uncomfortable addressing and managing comorbidities. 
Nevertheless, psychiatrists are crucial in the overall health of 
persons with schizophrenia because they are often the only 
health provider these patients will see (31). In this perspective, 
it is cogent for mental health providers to become competent in 
managing their patients’ physical health through proper training 
programs. Taking these into consideration, psychiatrists should 
ideally take the lead for the integrated education, assessment, and 
care of medical needs of their patients with mental illness.
Care for persons with severe mental illness is complex 
and highly interdisciplinary. It involves a variety of health 
professionals, including cardiologist, internist, endocrinologists, 
gynecologists, urologists, dieticians, and toxicologists. Based on 
the results of this survey, the authors believe that a future challenge 
for the management of patients with mental illness will be the 
classification of patients based on their risk of comorbidities, to 
help ensure optimal healthcare provision for those at greater risk 
of other illnesses. Endorsement from Italian medical societies 
and specialist associations may be beneficial in producing such 
guidelines and recommendations.
In this survey Italian psychiatrists describes themselves as 
careful healthcare providers for the physical illnesses of patients 
with schizophrenia, but with several substantial shortcomings. 
For instance, surveyed psychiatrists were mainly focused on 
substance and alcohol use disorders. Comorbid substance use 
disorders were associated with poorer clinical outcome and it 
might influence tolerability, efficacy, choice, and formulation of 
antipsychotics (32, 33), supporting the need to assess these dual 
disorders in patients with mental illness. However, the survey 
also revealed that psychiatrists did not put the same emphasis on 
the other important aspects of their patients’ daily life, including 
smoking and dietary habits, physical activity, behavioral 
addictions, and partner relationships.
FIgUrE 4 | Question—D10: Regardless of the type of patient, how often do you investigate the following aspects?
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In particular, it is important to highlight that sexual function 
was not frequently assessed by the surveyed psychiatrists when 
asked about their patients' daily life and regarding their decision 
of prescribing additional examinations. Up to 3% of prescribers 
reported assessing sexual functioning using specific psychometric 
tests, although a number of specific and well-validated tools are 
available and used outside the psychiatric community such as the 
International Index of Erectile Function (IIEF) and the Female 
Sexual Function Index (FSFI) that are self-report measures of sexual 
function (34, 35). This reluctance to monitor sexual activities has 
been previously reported (36) and, unfortunately, does not appear 
to be a priority for Italian specialists. Many psychiatrists and 
doctors in general are not trained to address sexual dysfunction 
and may thus feel embarrassed and uncomfortable addressing this 
topic (37). According to a report, low awareness of and attention 
to sexual dysfunction may have significant negative impacts on 
patients (38). However, sexual dysfunction assessment remains 
a challenge. The psychometric tools for assessment of sexual 
dysfunction are simple, easy to perform, and inexpensive, and 
consequently should be implemented in the healthcare systems 
(35). Moreover, health workers other than specialists may routinely 
administer these simple tests (39). Psychometric instruments 
addressing male and female sexual health can also indirectly but 
efficaciously reveal important information about the presence of 
non-communicable chronic diseases and lifestyle disorders (40–
42). Therefore, psychiatrists need to understand that investigating 
these areas not only responds to an unmet need of patients, but 
may also help in uncovering other critical physical comorbidities. 
In fact, sexual dysfunctions can be secondary to the disease itself 
or to comorbid physical disorders, or it may be an adverse effect 
of psychotropic drugs (43, 44). Importantly, the little attention 
given to the sexual sphere may have negative repercussions on 
patients' adherence and satisfaction with treatment, quality of 
life, and partner relationships (45). Although it was reported that 
people with stable schizophrenia were prone to rate their quality 
of life higher than healthy controls or clinicians would (46), high 
percentage of sexual dysfunction has been documented in the 
majority of patients with schizophrenia with negative impact on 
social adjustment and quality of life (47). Sexual functioning is 
also an important component of the bio-psycho-social model of 
FIgUrE 5 | Question—D11: And how often do you investigate the following aspects of everyday life?
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health, and is recognized also by the World Health Organization 
as a part of general health (36). Thus, sexual health should be 
considered as part and parcel of modern psychiatry to provide a 
more comprehensive and holistic care for patients with mental 
health disorders (40, 48).
limitations
Survey results were based on psychiatrists’ responses to the survey 
and is thus limited by the lack of objective data to quantify the 
examinations requested by clinicians. The survey responses are also 
subject to several biases, such as “wishful thinking” answers. For 
instance, despite the anonymity of the survey, some psychiatrists 
may still claim to perform several laboratory tests to show that 
they follow current treatment guidelines. These biases may be 
overcome in future studies by including patients’ families, who may 
provide more accurate information about patients’ lifestyle habits 
that can be addressed to improve their quality of life (49). Direct 
access to patient's medical records may also help narrow the gap 
between the information provided by individual specialists and the 
objectifiable clinical reality. In addition, a more accurate report of 
the background of the psychiatrists, an investigation of the clinical 
activities and the characteristics of study centers may be useful.
Nevertheless, this survey provides a preliminary description 
of the attitudes and opinions of Italian psychiatrists that may 
influence clinical practice.
COnClUSIOnS
In patients with schizophrenia, comorbidities and unhealthy 
lifestyle practices are associated with significant adverse 
physical and psychiatric outcomes (50). Therefore, routine 
clinical and laboratory monitoring are critical components of a 
comprehensive and integrated care program for this population.
This survey describes the quality of Italian psychiatrists’ care for 
patients with schizophrenia in terms of assessing comorbidities, 
frequency of medical assessments and use of available laboratory 
tests, frequency of clinical referrals, and use of psychometric tools 
for sexual dysfunction assessment. Mental healthcare providers 
should be responsible for the coordination of a multidisciplinary 
assessment and therapy, involving other medical specialists as 
needed. A successful strategy could be creating flow charts for 
integrated care pathways in patients with comorbidities or with 
high risk for comorbidities. Great attention must still be given 
to the patient's quality of life, especially concerning the sexual 
function area, with the aim of improving subjective well-being of 
people with severe mental illness (51, 52).
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